[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100454485":3},{"organization":4,"armGroups":7,"interventions":18,"overallOfficials":10,"centralContacts":24,"locations":30,"responsibleParty":51,"collaborators":55,"id":100,"slug":101,"hasResults":102,"nctId":103,"briefTitle":104,"officialTitle":105,"acronym":106,"eligibilityCriteria":107,"healthyVolunteers":102,"sex":108,"minAge":109,"maxAge":10,"enrollmentInfo":110,"targetDuration":113,"studyType":114,"phases":10,"briefSummary":115,"conditions":116,"keywords":118,"overallStatus":33,"whyStopped":10,"lastUpdateSubmitDate":125,"lastUpdatePostDateStruct":126,"startDateStruct":129,"completionDateStruct":131,"leadSponsor":133,"locationsCount":134},{"fullName":5,"class":6},"Second Xiangya Hospital of Central South University","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Advanced NSCLC patients with long-term benefit after first-line immunotherapy (Tumor-informed group)",null,"The ctDNA detection will be performed using a tumor-informed analysis approach. This method requires the availability of tumor tissue samples or a fixed-panel next-generation sequencing (NGS) test.",[13],"Diagnostic Test: ctDNA detection",{"label":15,"type":10,"description":16,"interventionNames":17},"Advanced NSCLC patients with long-term benefit after first-line immunotherapy (Tumor-agnostic group)","The ctDNA detection will be performed using a tumor-agnostic analysis. This method does not require tumor tissue samples or an NGS testing panel, or in cases where tissue samples are available but fail to meet quality control standards.",[13],[19],{"type":20,"name":21,"description":22,"armGroupLabels":23,"otherNames":10},"DIAGNOSTIC_TEST","ctDNA detection","High-depth sequencing method is used to detecting ctDNA.",[15,9],[25],{"name":26,"role":27,"phone":28,"phoneExt":10,"email":29},"Chunhong Hu, professor","CONTACT","+86 13508486908","huchunh5829@126.com",[31],{"facility":32,"status":33,"city":34,"state":35,"zip":36,"country":37,"countryCode":38,"cosmosGeoPoint":39,"geoPoint":44,"contacts":45},"Oncology Department，Second Xiangya Hospital of Central South University","RECRUITING","Changsha","Hunan","410011","China","CN",{"type":40,"coordinates":41},"Point",[42,43],112.97087,28.19874,{"lat":43,"lon":42},[46,47],{"name":26,"role":27,"phone":28,"phoneExt":10,"email":29},{"name":48,"role":27,"phone":49,"phoneExt":10,"email":50},"Fang Wu, professor","13574858332","wufang4461@csu.edu.cn",{"type":52,"investigatorFullName":53,"investigatorTitle":54,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"SPONSOR_INVESTIGATOR","Fang Wu","Associate Professor",[56,58,60,63,65,67,69,71,73,75,77,79,81,83,85,87,89,91,93,96,98],{"name":57,"class":6},"Sun Yat-Sen University Cancer Center",{"name":59,"class":6},"First Affiliated Hospital Xi'an Jiaotong University",{"name":61,"class":62},"Fujian Cancer Hospital","OTHER_GOV",{"name":64,"class":6},"Third Affiliated Hospital of Third Military Medical University",{"name":66,"class":6},"Xiangya Hospital of Central South University",{"name":68,"class":6},"Qinghai Province Fifth People's Hospital",{"name":70,"class":6},"Union Hospital, Tongji Medical College, Huazhong University of Science and Technology",{"name":72,"class":6},"Zhejiang Provincial People's Hospital",{"name":74,"class":6},"Hunan Province Tumor Hospital",{"name":76,"class":6},"Cancer Institute and Hospital, Chinese Academy of Medical Sciences",{"name":78,"class":6},"Second Affiliated Hospital, School of Medicine, Zhejiang University",{"name":80,"class":6},"Zhejiang Cancer Hospital",{"name":82,"class":6},"The First Affiliated Hospital of Guangzhou Medical University",{"name":84,"class":6},"Inner Mongolia People's Hospital",{"name":86,"class":6},"Guizhou Provincial People's Hospital",{"name":88,"class":6},"The Third Xiangya Hospital of Central South University",{"name":90,"class":6},"Yueyang Central Hospital",{"name":92,"class":6},"ZhuZhou Central Hospital",{"name":94,"class":95},"Zhangjiajie Affiliated Hospital of Hunan Normal University","UNKNOWN",{"name":97,"class":6},"Loudi Central Hospital",{"name":99,"class":95},"Chang Sha First Hospital","100454485","ctdna-analysis-to-monitor-the-risk-of-progression-after-first-line-immunotherapy-in-patients-with-advanced-nsclc-100454485",false,"NCT05198154","ctDNA Analysis to Monitor the Risk of Progression After First-line Immunotherapy in Patients With Advanced NSCLC","A Multicenter, Prospective Clinical Study of Circulating Tumor DNA Analysis to Monitor the Risk of Progression After Long-term Benefit to First-line Immunotherapy in Patients With Advanced NSCLC (CR1STAL)","CR1STAL","Inclusion Criteria:\n\n* Age ≥ 18 years old\n* Advanced non-small cell lung cancer (stage IIIB-IV), pathological types limited to squamous cell carcinoma or non-squamous cell carcinoma, driver gene mutations (EGFR\u002FALK\u002FROS1) were negative\n* General condition: ECOG score 0 or 1\n* First-line monotherapy or combination immunotherapy\n* The long-term benefit of immunotherapy was defined as PFS=12months\n* Tumor tissue samples can be obtained at the time of enrollment, and at least 5 \\~ 10 sections can be generated, and the pathological report indicates that the overall tumor content is not less than 10% or NGS testing with a fixed-panel is available; or no tumor tissue is available.\n* At least one measurable lesion (except patients with CR after first-line treatment) can be evaluated according to RECIST1.1 standard.\n* Have self-awareness, be able to understand the research scheme and voluntarily participate in the study, and can sign the informed consent form\n* Have good compliance, be able to cooperate with the collection of specimens from each node and provide corresponding clinical information.\n\nExclusion Criteria:\n\n* Serious primary diseases of the heart, liver and kidney\n* Other malignant tumors within 3 years prior to diagnosis of NSCLC\n* Women in pregnancy and lactation\n* The active stage of human immunodeficiency virus (HIV) infection\n* Patients with active systemic infection, pneumonia, tuberculosis, pericarditis\n* Patients who cannot understand the content of the experiment and cannot cooperate and refuse to sign informed consent.","ALL","18 Years",{"count":111,"type":112},100,"ESTIMATED","3 Years","OBSERVATIONAL","This study aims to explore the correlation of circulating tumor DNA(ctDNA) and the risk of progression in patients with advanced NSCLC who have long-term benefit from first-line immunotherapy (PFS 12 months)",[117],"Advanced Lung Non-Small Cell Carcinoma",[119,120,121,122,123,124],"ctDNA","advanced lung cancer","first-line immunotherapy","the risk of progression","minimal residual disease (MRD)","long-term benefit","2025-04-17",{"date":127,"type":128},"2025-04-23","ACTUAL",{"date":130,"type":128},"2022-01-24",{"date":132,"type":112},"2025-12-30",{"name":53,"class":6},1]